Rebecca Steenaard

Ms. Rebecca Steenaard

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
RSRebecca Steenaard
Rebecca Steenaard
LMLaura A. Michon
Laura A. Michon
HHHarm Haak
Harm Haak
Insight into the health-related quality of life (HRQoL) impact of adrenocortical carcinoma (ACC) is important. The disease and its treatment options potentially have an impact on HRQoL. For patients with limited survival, HRQoL research is of utmost importance. We will therefore provide an overview of HRQoL studies in patients with ACC. We found six studies that measured HRQoL in 323 patients with ACC (3 cross-sectional, 1 cohort, 2 trials), all indicating a reduced HRQoL compared to the general population. The FIRMACT trial found that HRQoL of patients with ACC was reduced compared to the general population, and that chemotherapy-mitotane further reduced HRQoL even though survival improved. Clinical aspects of the disease, including cortisol and aldosterone production and adrenal insufficiency have shown great impact on HRQoL in benign disease, even after the recovery of hormonal status. However, the impact of malignant adrenal disease and treatment options on HRQoL including adrenalectomy, radiotherapy, mitotane therapy, and chemotherapy have not been sufficiently studied in patients with ACC. Although the number of HRQoL studies in patients with ACC is limited, the existing literature does indicate that ACC has a large impact on patients’ HRQoL, with disease specific aspects. Further HRQoL research in patients with ACC is essential to improve patient-centered care, preferably by using an ACC-specific HRQoL questionnaire.

8 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RSRebecca Steenaard
Rebecca Steenaard
TKThomas M. A. Kerkhofs
Thomas M. A. Kerkhofs
MZMyrte Zijlstra
Myrte Zijlstra
FMFloortje Mols
Floortje Mols
MKMichiel N. Kerstens
Michiel N. Kerstens
HHHarm Haak
Harm Haak
We aimed to develop a disease-specific adrenocortical carcinoma (ACC) health-related quality of life (HRQoL) questionnaire (ACC-QOL) and assess HRQoL in a population-based cohort of patients with ACC. Development was in line with European Organization for Research and Treatment of Cancer (EORTC) guidelines, though not an EORTC product. In phase I and II, we identified 90 potential HRQoL issues using literature and focus groups, which were reduced to 39 by healthcare professionals. Pilot testing resulted in 28 questions, to be used alongside the EORTC QLQ-C30. In Phase III, 100 patients with ACC were asked to complete the questionnaires twice in the PROFILES registry (3-month interval, respondents: first 67, second 51). Confirmatory factor analysis demonstrated the structural validity of 26 questions with their scale structure (mitotane side-effects, hypercortisolism/hydrocortisone effects, emotional effects). Internal consistency and reliability were good (Cronbach’s alpha 0.897, Interclass correlation coefficient 0.860). Responsiveness analysis showed good discriminative ability (AUC 0.788). Patients diagnosed more than 5 years ago reported a good HRQoL compared with the Dutch reference population, but experienced residual fatigue and emotional problems. Patients who underwent recent treatment reported a lower HRQoL and problems in several domains. In conclusion, we developed an ACC-specific HRQoL questionnaire with good psychometric properties.

18 April 2022 in Discover Oncology
Verified
Journal Article
Open access
PDF file
RSRebecca Steenaard
Rebecca Steenaard
MRMarieke Rutjens
Marieke Rutjens
MEMadeleine H. T. Ettaieb
Madeleine H. T. Ettaieb
MNMax M. van Noesel
Max M. van Noesel
HHHarm R. Haak
Harm R. Haak
Adrenocortical carcinoma affects one in 5 million children each year. Since prognosis for children older than 4 years is limited, clinicians often choose aggressive treatment with etoposide, doxorubicin, cisplatin (EDP) and mitotane after resection. However, little is known about the impact of EDP-mitotane in children. We provide an overview of case-reports and case series listing side-effects and neurotoxicity of EDP-mitotane in children. Fourteen studies were identified describing a range of gastro-intestinal, endocrine, developmental and neuropsychological side-effects. Neurotoxicity included motor- and speech delay, decreased concentration and lower school performance. These side-effects appear to be reversible after mitotane discontinuation. We have added our own experience with a 10 year old girl with advanced adrenocortical carcinoma treated with EDP and 2 years of mitotane after irradical resection. She developed an impactful, but reversible, decrease in cognitive development measured by a standardized neuropsychological assessment before, during and after mitotane therapy. This decrease was mostly measurable in terms of decreased processing speed and concentration and a significant drop in school performance. Combined with fatigue and insecurity, this caused problems in short-term memory and the need to change her school type. In conclusion, EDP-mitotane is associated with several side-effects including neurotoxicity in pediatric cases, all reversible after mitotane discontinuation.

1 April 2020 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
RSRebecca Steenaard
Rebecca Steenaard
MKMarjolein N T Kremers
Marjolein N T Kremers
LMLaura A Michon
Laura A Michon
MZMyrte Zijlstra
Myrte Zijlstra
HHHarm Haak
Harm Haak
Little is known about the impact of adrenocortical carcinoma (ACC) on health-related quality of life (HRQoL), and no disease-specific questionnaire exists. This qualitative study aimed to identify relevant domains of HRQoL for patients with ACC. In 2 focus group interviews, we discussed concerns regarding living with ACC and its treatments. The first group consisted of 6 patients on mitotane therapy and their partners or relatives, the second group of 4 patients after surgery alone and their partners. Inductive qualitative content analysis was used to analyze the interviews. We identified 4 domains related to HRQoL in patients with ACC, namely physical complaints, mental consequences, social consequences, and functional limitations. For example, physical complaints included symptoms of the disease and side effects of mitotane therapy; mental consequences included feeling insecure and living from scan to scan; and functional limitations included daily activities and mobility. We further found that patients’ experiences with the health care system and health care professionals and partner perspectives influence HRQoL. In conclusion, ACC has a large impact on HRQoL in 4 domains. These results can be used to improve communication about HRQoL issues. We will use our findings to generate a disease-specific questionnaire to measure HRQoL in patients with ACC.

28 February 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
RSRebecca Steenaard
Rebecca Steenaard
JWJ Sofie de Wit
J Sofie de Wit
MRMarieke Rutjens
Marieke Rutjens
BBBabs van der Bruggen
Babs van der Bruggen
KBKarin Blijdorp
Karin Blijdorp
HHHarm Haak
Harm Haak
Purpose: We aimed to determine time trends in incidence, treatment and survival of patients with adrenocortical carcinoma in the Netherlands. Methods: All 685 adult patients with adrenocortical carcinoma diagnosed between 1993 and 2020 in the Netherlands were included, using the nation-wide prospective Netherlands Cancer Registry. Results: The median age-adjusted incidence rate based on the European Standard Population was 1.62 per million person-years [0.83-2.11] and was stable over time. We saw a gradual increase in stage III on diagnosis (13 to 25%) with a stable proportion of stage IV (40%). The five-year survival remained stable over time for stage I-II at 65% and stage III at 35%, while the survival for stage IV increased from 3% in 1993-1996 to 11% in 2017-2020. Since the Dutch Adrenal Network was founded in 2004, more patients were referred to an expert center (p<0.001), which was associated with increased survival (adjusted HR 0.70, 95%CI[0.57-0.85]). Multivariate cox-regression showed increased survival in all stages when treated with adrenalectomy (adjusted HR 0.53, 95%CI[0.43-0.65]) and mitotane therapy (adjusted HR 0.73, 95%CI[0.55-0.98]). In stage IV disease, adrenalectomy, surgical control of disease, chemotherapy and mitotane therapy were associated with increased survival. However, only 58% of mitotane users reached a therapeutic drug level and 59.5% discontinued treatment prematurely. Conclusions: The incidence of adrenocortical carcinoma is stable over time. The five-year survival for stage I-III remained stable, while the survival for stage IV increased. Factors associated with increased survival are centralization of care, adrenalectomy, surgical control of disease, chemotherapy and mitotane therapy.

31 August 2021 in Endocrine Abstracts
Verified
Journal Article
Closed access
RSRebecca Steenaard
Rebecca Steenaard
MRMarieke Rutjens
Marieke Rutjens
MEMadeleine H.T. Ettaieb
Madeleine H.T. Ettaieb
NVNoesel Max M. van
Noesel Max M. van
HHHarm R. Haak
Harm R. Haak
Background: One in 5 million children is affected by adrenocortical carcinoma (ACC) each year. Since prognosis for children older than 4 years is limited, clinicians often choose aggressive treatment with etoposide, doxorubicin, cisplatin (EDP) and mitotane after resection. However, little is known about the impact of EDP-mitotane on development in children. We therefore aimed to provide an overview of side-effects and neurocognitive effects of EDP-mitotane in children. Method: We searched PubMed for studies listing side-effects or cognitive development in pediatric cases with ACC or Cushing syndrome treated with EDP-mitotane. We have added our own case of a 10-year old girl with ACC treated with EDP-mitotane after irradical resection. Case: During EDP-mitotane she experienced several side-effects including nausea and hypothyroidism. She developed an impactful, but reversible, decrease in cognitive development measured by a standardized neuropsychological assessment before, during and after mitotane therapy. This decrease was mostly measurable in terms of decreased processing speed and concentration and a significant drop in school performance. Combined with fatigue and insecurity, this caused problems in short-term memory and the need to change her school type. Review: We found 14 case reports and case series listing side-effects and neurocognitive effects in children treated with EDP-mitotane. The studies listed gastro-intestinal, endocrine and developmental side-effects. Neurocognitive effects included motor- and speech delay, decreased concentration and lower school performance. Especially the gastro-intestinal and neurocognitive side-effects were reversible after mitotane discontinuation. Conclusion: EDP-mitotane is associated with several side-effects including neurocognitive effects in pediatric cases, all reversible after mitotane discontinuation. This can provide reassurance for clinicians, parents and patients in case mitotane therapy is indicated.